The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

Study Overview
=================
Brief Summary
-----------------
EGF is a polypeptide that promotes cell differentiation and collagen production while decreasing melanin production. This study is designed to study its effectiveness in improving the texture and appearance of facial skin after daily topical application. We hypothesized that EGF would improve facial skin hydration, elasticity, pigmentation, and wrinkles.

Detailed Description
-----------------
All patients gave written informed consent for epidermal growth factor serum application on the face. The pilot study enrolls thirty patients compared to pre and post-serum used to evaluate facial skin hydration, transepidermal water loss, elasticity, pigmentation, and wrinkles measured by corneometer, tewameter, cutometer, visioscan, and mexameter respectively on day 0, then 8, 12, and 16 weeks. The study evaluates subject satisfaction and side effects after serum application as secondary outcomes.

Official Title
-----------------
The Effectiveness of Epidermal Growth Factor Serum for the Improvement of Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles at the Institute of Dermatology: a Single-centered Pilot Study With a One-group Before-and-after Design

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Drug: Epidermal Growth Factor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thai Mild to moderate facial skin condition, as measured by 1-2 points on the hyperpigmentation status scale or 2-3 points on the wrinkle severity grading scale. Exclusion Criteria: Use of lotions or skin care products containing ingredients such as vitamin A/C, hydroquinone, or anti-aging agents. Sunbathing Hypersensitivity to serum components Pregnancy and breast-feeding Active skin diseases such as eczema or atopic dermatitis at the application site

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Epidermal Growth Factor Serum Application<br>Participants received Epidermal growth factor serum application on the face daily for two months compared to pre and post-results of skin quality. | Drug: Epidermal Growth Factor<br>* Apply facial twice daily.<br>* Other names: Epidermal Growth Factor Serum;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Facial skin hydration | measured by corneometer in arbitrary units (a.u.) on day 0, then 8, 12, and 16 weeks. | 4 months | 
| Transepidermal water loss | measured by tewameter in g/m2xh on day 0, then at 8, 12, and 16 weeks. | 4 months | 
| Facial skin elasticity | measured by the cutometer on day 0, then at 8, 12, and 16 weeks. | 4 months | 
| Facial skin wrinkles | Visioscan measurements were taken at day 0, then at 8, 12, and 16 weeks by using a 4-grade percentage wrinkle improvement scale. | 4 months | 
| Facial skin pigmentation | measured by mexameter on day 0, then at 8, 12, and 16 weeks. | 4 months | 
| Overall facial skin photograph | Using the subject global aesthetic improvement scale, two board-certified dermatologists evaluated a photo taken with Visia-CR on day 0, then at 8, 12, and 16 weeks. | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subject satisfaction in improving skin hydration, elasticity, wrinkles, and pigmentation | Using a quartile grading system, (0 = unsatisfied), (1 = slightly satisfied), (2 = satisfied), and (3 = very satisfied) | 4 months | 
| Adverse effects | Clinical follow-up at 2, 4, 8, 12, and 16 weeks | 4 months |